Jacquillat C, Chastang C, Tanzer J, Brière J, Weil M, Pereira-Neto M, Gemon-Auclerc M F, Schaison G, Domingo A, Boiron M, Bernard J
Boll Ist Sieroter Milan. 1978 Jul 31;57(3):237-46.
Between 1959 and 1973 were analyzed the records of 798 patients with chronic myelocytic leukemia. Mean survival (MS) for the entire group is 42 months. 342 patients have been followed closely during and after development of blastic transformation. Presence of following symptoms at the time of diagnosis: asthenia, weight loss, bone pain, fever, sweats and digestive disorders is of poor prognosis significance (MS: 36 months, no sign: MS 75 months) (P less than 0.001). Spleen size is also a prognostic factor. MS are respectively 70, 52 and 35 months if initial splenomegaly is moderate (less than 3 cm), marked (less than 6 cm) or tumoral (greater than or equal to 6 cm). Thrombocytopenia (less than 15,000/mm3 or thrombocythemia (greater than 1 million/mm3) have a poor prognosis with median survival 22 months and 28 months. If peripheral blast cells (hemocytoblasts + myeloblasts) exceed 5%, the prognosis is worse; beyond 10% MS is 26 months. In contrast certain factors have better prognosis: hemoglobin greater than or equal to 14 g/100 ml, young age (less than 20 y.) MS: 62 months), female sex and an initial WBC count below 25 x 10(3)/mm3 (MS: 70 months).
分析了1959年至1973年间798例慢性粒细胞白血病患者的记录。整个组的平均生存期（MS）为42个月。342例患者在发生原始细胞转化期间及之后得到密切随访。诊断时出现以下症状：乏力、体重减轻、骨痛、发热、盗汗和消化系统紊乱，预后不良（MS：36个月，无这些症状：MS 75个月）（P小于0.001）。脾脏大小也是一个预后因素。如果初始脾肿大为中度（小于3 cm）、显著（小于6 cm）或肿瘤样（大于或等于6 cm），平均生存期分别为70、52和35个月。血小板减少（小于15,000/mm³）或血小板增多（大于100万/mm³）预后不良，中位生存期分别为22个月和28个月。如果外周血原始细胞（成血细胞+原粒细胞）超过5%，预后更差；超过10%时，平均生存期为26个月。相比之下，某些因素预后较好：血红蛋白大于或等于14 g/100 ml、年轻（小于20岁，MS：62个月）、女性以及初始白细胞计数低于25×10³/mm³（MS：70个月）。
